Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) fell 4.6% on Monday . The stock traded as low as $4.58 and last traded at $4.58. 686,579 shares changed hands during mid-day trading, an increase of 626% from the average session volume of 94,574 shares. The stock had previously closed at $4.80.
Innovent Biologics Stock Performance
The stock has a 50 day moving average of $4.96 and a 200-day moving average of $5.18.
Innovent Biologics Company Profile
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Featured Articles
- Five stocks we like better than Innovent Biologics
- NYSE Stocks Give Investors a Variety of Quality Options
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 2 Drone Stocks Surging from Increased Media Attention
- Best Stocks Under $10.00
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
